维生素E治疗儿童非酒精性脂肪性肝病效果的Meta分析

刘申申; 邢怡青; 王宁; 余巧玲; 曾乐平

doi:10.3969/j.issn.1001-5256.2020.07.019

维生素E治疗儿童非酒精性脂肪性肝病效果的Meta分析

DOI: 10.3969/j.issn.1001-5256.2020.07.019

1. 中南大学湘雅医学院基础医学院
2. 中南财经政法大学公共管理学院

基金项目:

湖南省科技攻关计划(2018SK2095)；

详细信息

中图分类号: R725.7
计量
- 文章访问数: 1099
- HTML全文浏览量: 46
- PDF下载量: 166
- 被引次数: 0
出版历程
- 出版日期: 2020-07-20

Clinical effect of vitamin E in treatment of nonalcoholic fatty liver disease in children: A Meta-analysis

1. School of Basic Medical Sciences, Xiangya School of Medicine, Central South University, Changsha 410013, China
2. School of Public Administration, Zhongnan University of Economics and Law, Wuhan 430073, China

Research funding:

摘要

摘要:
目的评估维生素E对儿童非酒精性脂肪性肝病（NAFLD）的治疗效果。方法检索2019年12月前发表的关于维生素E治疗儿童NAFLD疗效的文章,检索范围包括Pub Med、Web of Science、The Cochran Library、Embase、OVID/NEJM、中国知网、万方数据库。分析数据包含BMI、肝酶水平（ALT、AST）、血脂水平（TG、TC、LDL、HDL）、肝脂肪变性缓解率共8个参数。使用REVMAN5. 3进行Meta分析。连续变量选择标准化均数差（SMD）和95%可信区间（CI）计算和分析干预前后参数的差异,分类变量选择风险差（RD）和95%CI进行分析。非异质性数据采用固定效应模型,否则采用随机效应模型。发表偏倚的评估通过漏斗图完成。结果共检索到599篇文章,其中9篇纳入Meta分析,受试者607例。维生素E显著改善了患儿的ALT水平（SMD=-0. 27,95%CI:-0. 48～-0. 06,P=0. 01）,但是对患儿的BMI水平（SMD=-0. 09,95%CI:-0. 28～0. 10,P=0. 34）、AST水平（SMD=-0. 20,95%CI...
- 非酒精性脂肪性肝病 /
- 维生素E /
- 儿童 /
- Meta分析(主题)
Abstract:
Objective To investigate the clinical effect of vitamin E in the treatment of nonalcoholic fatty liver disease( NAFLD) in children. Methods PubMed,Web of Science,The Cochran Library,Embase,OVID/NEJM,CNKI,and Wanfang Data were searched for the articles on vitamin E in the treatment of NAFLD in children published up to December 2019. The data of 8 parameters were analyzed,i. e.,body mass index( BMI),liver enzymes [alanine aminotransferase( ALT) and aspartate aminotransferase( AST) ],blood lipid levels [triglyceride( TG),total cholesterol( TC),low-density lipoprotein( LDL),and high-density lipoprotein( HDL) ],and remission rate of hepatic steatosis. RevMan 5. 3 was used to perform a Meta-analysis. Continuous variables were analyzed by standardized mean difference( SMD) and 95% confidence interval( CI),and the changes after intervention were analyzed; categorical variables were analyzed by risk difference( RD) and 95% CI. A fixed effects model was used for homogeneous data,and a random effects model was used for heterogeneous data. Funnel plots were used to evaluate publication bias. Results A total of 599 articles were retrieved,among which 9 were included in the Meta-analysis,with 607 subjects in total. Vitamin E significantly improved the level of ALT( SMD =-0. 27,95% CI:-0. 48 to-0. 06,P = 0. 01),but it did not improve the levels of BMI( SMD =-0. 09,95% CI:-0. 28 to 0. 10,P = 0. 34),AST( SMD =-0. 20,95% CI:-0. 42 to 0. 02,P = 0. 07),TG( SMD =-0. 19,95% CI:-0. 51 to 0. 12,P = 0. 22),TCHO( SMD =-0. 11,95% CI:-0. 31 to 0. 08,P = 0. 24),HDL( SMD =-0. 02,95% CI:-0. 27 to 0. 23,P = 0. 88),LDL( SMD =-0. 04,95% CI:-0. 27 to0. 19,P = 0. 72),and the remission rate of hepatic steatosis( RD = 0. 06,95% CI:-0. 05 to 0. 17,P = 0. 29). Conclusion Vitamin E can significantly improve the level of ALT in children with NAFLD and can be considered as an adjuvant drug for clinical treatment.
- non-alcoholic fatty liver disease /
- vitamin E /
- child /
- Meta-analysis as topic

HTML全文

参考文献(35)

[1]COBBINA E,AKHLAGHI F.Non-alcoholic fatty liver disease(NAFLD)-pathogenesis,classification,and effect on drug metabolizing enzymes and transporters[J].Drug Metab Rev,2017,49(2):197-211．

[2]MENCIN AA,LAVINE JE.Nonalcoholic fatty liver disease in children[J].Curr Opin Clin Nutr Metab Care,2011,14(2):151-157．

[3]BYRNE CD,TARGHER G.NAFLD:A multisystem disease[J].JHepatol,2015,62(1 Suppl):s47-s64．

[4]RINELLA ME,SANYAL AJ.Management of NAFLD:A stage-based approach[J].Nat Rev Gastroenterol Hepatol,2016,13(4):196-205．

[5]HARDWICK RN,FISHER CD,CANET MJ,et al.Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease[J].Drug Metab Dispos,2010,38(12):2293-2301．

[6]PIRGON，BILGIN H，EKMEZ F,et al.Association between insulin resistance and oxidative stress parameters in obese adolescents with non-alcoholic fatty liver disease[J].J Clin Res Pediatr Endocrinol,2013,5(1):33-39．

[7]DU J,MA YY,YU CH,et al.Effects of pentoxifylline on nonalcoholic fatty liver disease:A Meta-analysis[J].World J Gastroenterol,2014,20(2):569-577．

[8]HIGGINS JP,THOMPSON SG,DEEKS JJ,et al.Measuring inconsistency in meta-analyses[J].BMJ,2003,327(7414):557-560．

[9]VAJRO P,MANDATO C,FRANZESE A,et al.Vitamin E treatment in pediatric obesity-related liver disease:A randomized study[J].J Pediatr Gastroenterol Nutr,2004,38(1):48-55．

[10]NOBILI V,MANCO M,DEVITO R,et al.Effect of vitamin E on aminotransferase levels and insulin resistance in children with nonalcoholic fatty liver disease[J].Aliment Pharmacol Ther,2006,24(11-12):1553-1561．

[11]NOBILI V,MANCO M,DEVITO R,et al.Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease:Arandomized,controlled trial[J].Hepatology,2008,48(1):119-128．

[12]WANG CL,LIANG L,FU JF,et al.Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children[J].World J Gastroenterol,2008,14(10):1598-1602．

[13]LAVINE JE,SCHWIMMER JB,van NATTA ML,et al.Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents:The TONIC randomized controlled trial[J].JAMA,2011,305(16):1659-1668．

[14]D'ADAMO E,MARCOVECCHIO ML,GIANNINI C,et al.Improved oxidative stress and cardio-metabolic status in obese prepubertal children with liver steatosis treated with lifestyle combined with Vitamin E[J].Free Radic Res,2013,47(3):146-153．

[15]GHERGHEREHCHI R,HAZHIR N,MOSTAFA GHAREBAGHI M.Lifestyle intervention and vitamin E therapy in obese children with nonalcoholic fatty liver disease[J].J Compr Ped,2013,4(1):62-65．

[16]MURER SB,AEBERLI I,BRAEGGER CP,et al.Antioxidant supplements reduced oxidative stress and stabilized liver function tests but did not reduce inflammation in a randomized controlled trial in obese children and adolescents[J].J Nutr,2014,144(2):193-201．

[17]NOBILI V,ALISI A,MOSCA A,et al.The antioxidant effects of hydroxytyrosol and vitamin E on pediatric nonalcoholic fatty liver disease,in a clinical trial:A new treatment[J].Antioxid Redox Signal,2019,31(2):127-133．

[18]HASHIMOTO E,TOKUSHIGE K,LUDWIG J.Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis:Current concepts and remaining challenges[J].Hepatol Res,2015,45(1):20-28．

[19]TILG H,MOSCHEN AR.Evolution of inflammation in nonalcoholic fatty liver disease:The multiple parallel hits hypothesis[J].Hepatology,2010,52(5):1836-1846．

[20]DAY CP.Pathogenesis of steatohepatitis[J].Best Pract Res Clin Gastroenterol,2002,16(5):663-678．

[21]LEVENE AP,GOLDIN RD.The epidemiology,pathogenesis and histopathology of fatty liver disease[J].Histopathology,2012,61(2):141-152．

[22]SPAHIS S,DELVIN E,BORYS JM,et al.Oxidative stress as a critical factor in nonalcoholic fatty liver disease pathogenesis[J].Antioxid Redox Signal,2017,26(10):519-541．

[23]HICKMAN I,MACDONALD G.Is vitamin E beneficial in chronic liver disease?[J].Hepatology,2007,46(2):288-290．

[24]MENG XY,LIU J,WANG L,et al.Effects of ascorbic acid-polyethyleneimine carbon dots on proliferation,apoptosis and oxidative stress of MG63 cells by Golgi stress[J].J Jilin Univ(Med Edit),2019,45(6):1218-1223,1480.(in Chinese)孟许亚，刘杰，王璐，等．抗坏血酸-聚乙烯亚胺复合碳点通过高尔基体应激对MG63细胞增殖、凋亡和氧化应激的影响[J]．吉林大学学报(医学版)，2019,45(6):1218-1223,1480．

[25]CHALASANI N,DEEG MA,CRABB DW.Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis[J].Am J Gastroenterol,2004,99(8):1497-1502．

[26]SEKI S,KITADA T,YAMADA T,et al.In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases[J].J Hepatol,2002,37(1):56-62．

[27]SARKHY AA,AL-HUSSAINI AA,NOBILI V.Does vitamin E improve the outcomes of pediatric nonalcoholic fatty liver disease?A systematic review and meta-analysis[J].Saudi J Gastroenterol,2014,20(3):143-153．

[28]SATO K,GOSHO M,YAMAMOTO T,et al.Vitamin E has a beneficial effect on nonalcoholic fatty liver disease:A meta-analysis of randomized controlled trials[J].Nutrition,2015,31(7-8):923-930．

[29]PHUNG N,PERA N,FARRELL G,et al.Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis[J].Int J Mol Med,2009,24(2):171-180．

[30]MANCO M,ALISI A,NOBILI V.Risk of severe liver disease in NAFLD with normal ALT levels:A pediatric report[J].Hepatology,2008,48(6):2087-2088．

[31]WIECKOWSKA A,MCCULLOUGH AJ,FELDSTEIN AE.Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis:Present and future[J].Hepatology,2007,46(2):582-589．

[32]SAKR HF,ABBAS AM,HAIDARA MA.Swimming,but not vitamin E,ameliorates prothrombotic state and hypofibrinolysis in a rat model of nonalcoholic fatty liver disease[J].J Basic Clin Physiol Pharmacol,2018,29(1):61-71．

[33]KIM GH,CHUNG JW,LEE JH,et al.Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome:A propensity score-matched cohort study[J].Clin Mol Hepatol,2015,21(4):379-386．

[34]SANYAL AJ,CHALASANI N,KOWDLEY KV,et al.Pioglitazone,vitamin E,or placebo for nonalcoholic steatohepatitis[J].N Engl JMed,2010,362(18):1675-1685．

[35]WITTLIN L,LOGOMARSINO JV.Therapeutic effects of vitamin Esupplementation in liver diseases and transplantation[J].J Gastroenterol Hepatol Res,2014,3:1095-1102.

施引文献

资源附件(0)

访问统计